Eli Lilly Hedged Depositary Receipts Stock
StockStockPrice
Historical dividends and forecast
Eli Lilly Hedged Depositary Receipts has so far distributed 0.107 in 2024. The next dividend will be paid on 17.12.2024
CHART BY
Frequently asked questions
What is Eli Lilly Hedged Depositary Receipts's market capitalization?
What is Eli Lilly Hedged Depositary Receipts's Price-to-Earnings (P/E) ratio?
What is the Earnings Per Share (EPS) for Eli Lilly Hedged Depositary Receipts?
What are the analyst ratings and target price for Eli Lilly Hedged Depositary Receipts's stock?
What is Eli Lilly Hedged Depositary Receipts's revenue over the trailing twelve months?
Is Eli Lilly Hedged Depositary Receipts paying dividends?
What is the EBITDA for Eli Lilly Hedged Depositary Receipts?
What is the free cash flow of Eli Lilly Hedged Depositary Receipts?
What is the 5-year beta of Eli Lilly Hedged Depositary Receipts's stock?
How many employees does Eli Lilly Hedged Depositary Receipts have, and what sector and industry does it belong to?
What is the free float of Eli Lilly Hedged Depositary Receipts's shares?
Financials
Market Cap
$804.85B5Y beta
0.42EPS (TTM)
9.258Free Float
948.96MP/E ratio (TTM)
91.47Revenue (TTM)
$40.86BEBITDA (TTM)
$16.11BFree Cashflow (TTM)
-$6.81BAnalyst Ratings
The price target is $865.62 and the stock is covered by 27 analysts.
Buy
21
Hold
6
Sell
0
Information
Eli Lilly and Company is a medicine company. The Company discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its diabetes, obesity and other cardiometabolic products include Basaglar, Humalog, Mounjaro, Trulicity and Zepbound. Its oncology products include Alimta, Retevmo, Tyvyt and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh and Taltz. Its neuroscience products include Cymbalta and Emgality. Its other products and therapies include Cialis and Forteo. It manufactures and distributes its products through facilities in the United States (U.S.), including Puerto Rico, and in Europe and Asia. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing, as well as clinical and pre-clinical radioligand therapies. It is also developing oral small molecule inhibitor of α4β7 integrin (known as MORF-057) for inflammatory bowel disease (IBD).
43,000
Biotechnology & Drugs
Health Care
Identifier
ISIN
Primary Ticker